coronary artery disease
Conditions
Interventions
None listed
Sponsors
Shinshu University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients planned for percutaneous coronary intervention (PCI) and treated with dual antiplatelet therapy (DAPT) using aspirin and prasugrel
Exclusion criteria
Exclusion criteria: 1.Patients unable to continue dual antiplatelet therapy (DAPT) for more than one month after PCI. 2.Patients currently taking non-steroidal anti-inflammatory drugs (NSAIDs). 3.Patients undergoing anticoagulation therapy (warfarin or novel anticoagulants). 4.Patients taking clopidogrel, cilostazol, or ticagrelor. 5.Patients with a platelet count of less than 100,000/microL at the time of enrollment. 6.Patients with hemoglobin levels less than 8 g/dL at the time of enrollment. 7.Patients with severe renal dysfunction (creatinine >= 2 mg/dL). 8.Patients who cannot provide informed consent. 9.Patients with a life expectancy of less than one year. 10.Patients judged by to be inappropriate as a research subject by investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet-derived thrombogenicity (area under the flow-pressure curve for platelet chip (PL-AUC)) as assessed by total thrombus-formation analysis system (T-TAS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Maximum platelet aggregation rate (MPR) measured by light transmission aggregometry (LTA) with ADP 20 microM and collagen 10 microM PRU (P2Y12 reaction unit) and ARU (aspirin reaction unit) measured by VerifyNow | — |
Countries
Japan
Contacts
Public ContactTadashi Itagaki
Shinshu University Hospital Department of Cardiovascular Medicine
Outcome results
None listed